NeuroTherapia Receives Grant from Alzheimer’s Association for Development of First-in-Class Drug for Alzheimer’s Disease

NeuroTherapia, an early-stage clinical pharmaceutical company, announced today that it has received a grant from the Alzheimer’s Association Part the Cloud program for the development of its first-in-class drug, NTRX-07, for the treatment of Alzheimer’s disease (AD).

Digital Science boosts pharma industry support following OntoChem acquisition

Digital Science is positioning itself to play an even greater role in the pharmaceutical industry’s all-important drug discovery, by helping industry sift through a sea of information and focus on the research that matters.

Study: Drug May Delay Earliest Symptoms of Multiple Sclerosis

A drug called teriflunomide may delay first symptoms for people whose magnetic resonance imaging (MRI) scans show signs of multiple sclerosis (MS) even though they do not yet have symptoms of the disease. The preliminary study, released April 19, 2023, will be presented at the American Academy of Neurology’s 75th Annual Meeting, being held in person in Boston and live online from April 22-27, 2023. Called radiologically isolated syndrome, the condition is diagnosed in people who do not have MS symptoms but who have abnormalities in the brain or spinal cord called lesions, similar to those seen in MS.

‘Carb’ Treatment for Stroke Receives New U.S. Patent

A new twist on a drug used to treat alcohol use disorder could double up as a treatment for stroke. Called “Carb” for short, this new formulation is designed to treat ischemic stroke, protect brain tissue against injury and minimize the size of a brain infarct.

National Primate Research Center of Thailand Chulalongkorn University Symposium 2023

As its 11th-anniversary approaches, the National Primate Research Center of Thailand Chulalongkorn University (NPRCT-CU) and the Primates Enterprise Co., Ltd. are pleased to announce two events in February 2023:

Intravesical chemotherapy combination provides effective treatment alternative for high-risk non-muscle invasive bladder cancer

A combination of two intravesical chemotherapy drugs – gemcitabine and docetaxel – yields high response rates with good tolerability in patients with high-risk non-muscle-invasive bladder cancer (NMIBC), reports a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

“Read Medicine Labels” – How to Safely Use Green Chiretta Against COVID-19

Chula Pharmaceutical Science urges consumers to pay attention to “medicine labels” to choose and use green chiretta (Andrographis paniculata) effectively and safely. They also cautioned that the government should modify the labels, and control the price of herbal medicines that help in curbing the current pandemic.

Chula Taps into Medical Cannabis and Expands the Product Line

“Cannabis” is a high-value cash crop with immense benefits in medicine, health, nutrition, and beauty. As soon as the Thai government had given the green light, Chulalongkorn was ready to join hands with the private sector and concerning government agencies to accelerate the research and development of a vast assortment of cannabis products.

March SLAS Discovery Explores COVID-19 Drug Therapies Six Months Later

The March edition of SLAS Discovery features the cover article, “Therapeutic and Vaccine Options for COVID-19: Status After 6 Months of the Disease Outbreak” by Christian Ogaugwu (Federal University Oye-Ekiti, Ekiti State, Nigeria ), Dawid Maciorowski, Subba Rao Durvasula, Ph.D., Ravi Durvasula, M.D., and Adinarayana Kunamneni, Ph.D. (Loyola University Medical Center, Maywood, IL, USA).

Memorial Sloan Kettering Awards and Appointments

Memorial Sloan Kettering Cancer Center (MSK) announces its most recent awards and appointments for the institution’s physicians, scientists, nurses, and staff.

Researchers use live virus to identify 30 existing drugs that could treat COVID-19

Scientists at Sanford Burnham Prebys Medical Discovery Institute, the University of Hong Kong, Scripps Research, UC San Diego School of Medicine, the Icahn School of Medicine at Mount Sinai and UCLA have identified 30 existing drugs that stop the replication of SARS-CoV-2, the virus that causes COVID-19. The study was placed on bioRxiv (pronounced “bio-Archive”), an open-access distribution service for preprints of life science research.

Major Asian Gene Study to Help Doctors Battle Disease

“Under-representation of Asian populations in genetic studies has meant that medical relevance for more than half of the human population is reduced,” one researcher said.